Compare Merck & Co., Inc. (MRK) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Teucrium Wheat Fund — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Teucrium Wheat Fund trades at $25.21. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals.
| MRK | WEAT | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.52 | $25.49 |
52-Week Low | $77.60 | $19.88 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
WEAT, the Teucrium Wheat Fund ETF, trades at $24.99, down 1.03% on the day, yet maintains a strong bullish technical trend with moving averages signaling buy. The fund has surged approximately 25% year-to-date, driven by wheat price increases and supply concerns highlighted by recent USDA production cuts. However, oscillators indicate potential short-term overbought conditions with RSI readings above 80.
The outlook for WEAT remains positive given fundamental agricultural supply constraints and inflation trends, but faces risks from potential price corrections after rapid gains and broader commodity market volatility. Investment appeal hinges on continued wheat market strength, though current technical indicators suggest caution for near-term entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
